Abstract:Nerve stimulation‐evoked contraction of muscles from mild MuSK myasthenia gravis mice (injected with low doses patient IgG4) appeared partly insensitive to μ‐Conotoxin‐GIIIB. This blocker of NaV1.4 voltage‐gated sodium channels normally completely eliminates muscle contraction. We studied neuromuscular transmission and possible compensatory expression of NaV1.5 (cardiac‐type) channels but showed this was not the case. Which other Na channel types or related factors are involved remains to be seen. Muscle‐specific kinase myasthenia gravis (MuSK MG) is caused by autoantibodies against MuSK in the neuromuscular junction (NMJ). MuSK MG patients have fluctuating, fatigable skeletal muscle weakness, in particular of bulbar muscles. Severity differs greatly between patients, in spite of comparable autoantibody levels. One explanation for inter‐patient and inter‐muscle variability in sensitivity might be variations in compensatory muscle responses. Previously, we developed a passive transfer mouse model for MuSK MG. In preliminary ex vivo experiments, we observed that muscle contraction of some mice, in particular those with milder myasthenia, had become partially insensitive to inhibition by μ‐Conotoxin‐GIIIB, a blocker of skeletal muscle NaV1.4 voltage‐gated sodium channels. We hypothesised that changes in NaV channel expression profile, possibly co‐expression of (μ‐Conotoxin‐GIIIB insensitive) NaV1.5 type channels, might lower the muscle fibre's firing threshold and facilitate neuromuscular synaptic transmission. To test this hypothesis, we here performed passive transfer in immuno‐compromised mice, using 'high', 'intermediate' and 'low' dosing regimens of purified MuSK MG patient IgG4. We compared myasthenia levels, μ‐Conotoxin‐GIIIB resistance and muscle fibre action potential characteristics and firing thresholds. High‐ and intermediate‐dosed mice showed clear, progressive myasthenia, not seen in low‐dosed animals. However, diaphragm NMJ electrophysiology demonstrated almost equal myasthenic severities amongst all regimens. Nonetheless, low‐dosed mouse diaphragms showed a much higher degree of μ‐Conotoxin‐GIIIB resistance. This was not explained by upregulation of Scn5a (the NaV1.5 gene), lowered muscle fibre firing thresholds or histologically detectable upregulated NaV1.5 channels. It remains to be established which factors are responsible for the observed μ‐Conotoxin‐GIIIB insensitivity and whether the NaV repertoire change is compensatory beneficial or a bystander effect.

A class of chemical compounds enhances clustering of muscle nicotinic acetylcholine receptor in cultured myogenic cells

Non-neuronal cholinergic activity is potentiated in myasthenia gravis

Modulation of the Acetylcholine Receptor Clustering Pathway Improves Neuromuscular Junction Structure and Muscle Strength in a Mouse Model of Congenital Myasthenic Syndrome

IgG1-3 MuSK Antibodies Inhibit AChR Cluster Formation, Restored by SHP2 Inhibitor, Despite Normal MuSK, DOK7, or AChR Subunit Phosphorylation

Secreted Signaling Molecules at the Neuromuscular Junction in Physiology and Pathology

Tyrosine phosphatase regulation of MuSK-dependent acetylcholine receptor clustering.

Muscle-Specific Receptor Tyrosine Kinase Endocytosis in Acetylcholine Receptor Clustering in Response to Agrin

The Effect of Skeletal Muscle-Specific Creatine Treatment on ALS NMJ Integrity and Function

Regulation of Ach Receptor Clustering by the Tyrosine Phosphatase Shp2

Synthesis and Biological Evaluation of Novel MB327 Analogs as Resensitizers for Desensitized Nicotinic Acetylcholine Receptors after Intoxication with Nerve Agents

The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis

MuSK levels differ between adult skeletal muscles and influence postsynaptic plasticity.

Insights into the Structural Determinants Required for High-Affinity Binding of Chiral Cyclopropane-Containing Ligands to Α4β2-Nicotinic Acetylcholine Receptors: an Integrated Approach to Behaviorally Active Nicotinic Ligands

Synthesis and Biological Evaluation of Novel Hybrids of Highly Potent and Selective Α4β2-Nicotinic Acetylcholine Receptor (nachr) Partial Agonists.

New insights into the effects of organometallic ruthenium complexes on nicotinic acetylcholine receptors

Alanine-Scanning Mutagenesis of Α-Conotoxin GI Reveals the Residues Crucial for Activity at the Muscle Acetylcholine Receptor

Achieving Acetylcholine Receptor Clustering in Tissue-Engineered Skeletal Muscle Constructs In vitro through a Materials-Directed Agrin Delivery Approach

The Ig1/2 domain of MuSK binds to muscle surface and is involved in acetylcholine receptor clustering.

Autoimmune mechanisms elucidated through muscle acetylcholine receptor structures

Regulation of AChR Clustering by Dishevelled Interacting with MuSK and PAK1

Change of voltage‐gated sodium channel repertoire in skeletal muscle of a MuSK myasthenia gravis mouse model